Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2025-02-27 Sale |
2025-03-03 4:27 pm |
NovoCure Ltd | NVCR | Leonard Frank X EVP, Pres., Novocure Oncology |
15,036 | $19.7 | $296,257 | 146,200 (Direct) |
View |
| 2025-02-27 Sale |
2025-03-03 4:26 pm |
NovoCure Ltd | NVCR | Cordova Ashley Chief Executive Officer |
13,494 | $19.72 | $266,126 | 206,058 (Direct) |
View |
| 2025-02-27 Sale |
2025-03-03 4:26 pm |
NovoCure Ltd | NVCR | Paravasthu Mukund Chief Operating Officer |
2,014 | $19.71 | $39,688 | 29,423 (Direct) |
View |
| 2025-01-11 Sale |
2025-01-15 4:23 pm |
NovoCure Ltd | NVCR | Paravasthu Mukund Chief Operating Officer |
2,160 | $26.81 | $57,906 | 31,437 (Direct) |
View |
| 2024-11-02 Sale |
2024-11-06 4:27 pm |
NovoCure Ltd | NVCR | Paravasthu Mukund Chief Operating Officer |
44 | $16.69 | $734 | 79,217 (Direct) |
View |
| 2024-10-31 Sale |
2024-11-04 4:34 pm |
NovoCure Ltd | NVCR | Puri Michal Nath Chief Human Resources Officer |
810 | $15.79 | $12,792 | 110,093 (Direct) |
View |
| 2024-11-01 Sale |
2024-11-04 4:34 pm |
NovoCure Ltd | NVCR | Leonard Frank X EVP, Pres., Novocure Oncology |
598 | $15.94 | $9,531 | 161,236 (Direct) |
View |
| 2024-11-01 Sale |
2024-11-04 4:32 pm |
NovoCure Ltd | NVCR | Paravasthu Mukund Chief Operating Officer |
160 | $15.88 | $2,540 | 3,503 (Direct) |
View |
| 2024-08-02 Sale |
2024-08-05 4:25 pm |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
688 | $20.14 | $13,857 | 219,179 (Direct) |
View |
| 2024-06-04 Sale |
2024-06-06 5:43 pm |
NovoCure Ltd | NVCR | VERNON W ANTHONY Director |
964 | $23.89 | $23,033 | 176,079 (Direct) |
View |
| 2024-06-04 Sale |
2024-06-06 5:42 pm |
NovoCure Ltd | NVCR | Scannell Timothy J Director |
964 | $23.89 | $23,027 | 14,210 (Direct) |
View |
| 2024-06-04 Sale |
2024-06-06 5:42 pm |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
964 | $23.89 | $23,025 | 89,421 (Direct) |
View |
| 2024-03-01 Sale |
2024-03-05 4:09 pm |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
3,324 | $16.02 | $53,253 | 251,235 (Direct) |
View |
| 2024-03-01 Sale |
2024-03-05 4:08 pm |
NovoCure Ltd | NVCR | Leonard Frank X EVP, Pres., Novocure Oncology |
2,519 | $16.02 | $40,358 | 160,098 (Direct) |
View |
| 2024-02-28 Sale |
2024-02-29 4:38 pm |
NovoCure Ltd | NVCR | Leonard Frank X EVP, Pres., Novocure Oncology |
2,078 | $16.14 | $33,545 | 318,965 (Direct) |
View |
| 2024-02-28 Sale |
2024-02-29 4:28 pm |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
2,303 | $16.14 | $37,177 | 326,479 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
Ownership |
2025-01-06 4:10 pm |
N/A N/A |
NovoCure Ltd | NVCR | Brackmann Christoph CFO |
0 | $0 | 162,717 (Direct) |
View |
| 2024-12-31 Option Award |
2025-01-03 4:04 pm |
N/A N/A |
NovoCure Ltd | NVCR | Ben Arye Barak General Counsel |
669 | $14.75 | 118,721 (Direct) |
View |
| 2024-12-31 Option Award |
2025-01-03 4:04 pm |
N/A N/A |
NovoCure Ltd | NVCR | Cordova Ashley Chief Executive Officer |
373 | $14.75 | 219,552 (Direct) |
View |
| 2025-01-01 Option Award |
2025-01-03 4:04 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf Director |
400,000 | $0 | 415,640 (Direct) |
View |
| 2024-12-31 Option Award |
2025-01-03 4:04 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf Director |
412 | $14.75 | 415,640 (Direct) |
View |
| 2024-11-04 Option Award |
2024-11-06 4:27 pm |
N/A 2034-11-03 |
NovoCure Ltd | NVCR | Paravasthu Mukund Chief Operating Officer |
45,620 | $16.59 | 79,217 (Direct) |
View |
| 2024-11-04 Option Award |
2024-11-06 4:27 pm |
N/A N/A |
NovoCure Ltd | NVCR | Paravasthu Mukund Chief Operating Officer |
30,138 | $0 | 79,217 (Direct) |
View |
Ownership |
2024-10-09 6:21 pm |
N/A N/A |
NovoCure Ltd | NVCR | Paravasthu Mukund Chief Operating Officer |
0 | $0 | 134,850 (Direct) |
View |
| 2024-06-28 Option Award |
2024-08-06 4:22 pm |
N/A N/A |
NovoCure Ltd | NVCR | Ben Arye Barak General Counsel |
930 | $12.24 | 118,052 (Direct) |
View |
| 2024-06-28 Option Award |
2024-08-06 4:21 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
1,055 | $12.24 | 252,290 (Direct) |
View |
| 2024-06-28 Option Award |
2024-08-06 4:19 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf Chief Executive Officer |
1,239 | $12.24 | 15,228 (Direct) |
View |
| 2024-06-28 Option Award |
2024-08-06 4:19 pm |
N/A N/A |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
1,286 | $12.24 | 220,465 (Direct) |
View |
| 2024-06-28 Option Award |
2024-08-06 4:17 pm |
N/A N/A |
NovoCure Ltd | NVCR | Leonard Frank X EVP, Pres., Novocure Oncology |
1,736 | $12.24 | 161,834 (Direct) |
View |
| 2024-06-28 Option Award |
2024-08-06 4:16 pm |
N/A N/A |
NovoCure Ltd | NVCR | Puri Michal Nath Chief Human Resources Officer |
1,736 | $12.24 | 110,903 (Direct) |
View |
| 2024-06-05 Exercise |
2024-06-07 4:06 pm |
N/A 2027-02-21 |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
124,373 | $22.82 | 470,608 (Indirect) |
View |
| 2024-06-05 Option Award |
2024-06-06 6:37 pm |
N/A 2034-06-04 |
NovoCure Ltd | NVCR | Ocean Allyson J Director |
10,282 | $0 | 10,282 (Direct) |
View |
| 2024-06-05 Option Award |
2024-06-06 6:13 pm |
N/A 2034-06-04 |
NovoCure Ltd | NVCR | Madden Martin J. Director |
10,282 | $0 | 25,902 (Direct) |
View |
| 2024-06-05 Option Award |
2024-06-06 5:55 pm |
N/A 2034-06-04 |
NovoCure Ltd | NVCR | Hung David Director |
10,282 | $0 | 19,423 (Direct) |
View |
| 2024-06-05 Option Award |
2024-06-06 5:43 pm |
N/A 2034-06-04 |
NovoCure Ltd | NVCR | Stafford Kristin Director |
10,282 | $0 | 10,282 (Direct) |
View |
| 2024-06-05 Option Award |
2024-06-06 5:43 pm |
N/A 2034-06-04 |
NovoCure Ltd | NVCR | VERNON W ANTHONY Director |
10,282 | $0 | 176,079 (Direct) |
View |
| 2024-06-05 Option Award |
2024-06-06 5:42 pm |
N/A 2034-06-04 |
NovoCure Ltd | NVCR | Scannell Timothy J Director |
10,282 | $0 | 14,210 (Direct) |
View |
| 2024-06-05 Option Award |
2024-06-06 5:42 pm |
N/A 2034-06-04 |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
10,282 | $0 | 89,421 (Direct) |
View |
| 2024-06-05 Option Award |
2024-06-06 5:09 pm |
N/A 2034-06-04 |
NovoCure Ltd | NVCR | HILLEMAN JERYL L Director |
10,282 | $0 | 12,819 (Direct) |
View |
| 2024-02-27 Option Award |
2024-02-29 4:43 pm |
2025-02-27 2034-02-26 |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
258,597 | $16.3 | 376,215 (Direct) |
View |
| 2024-02-27 Option Award |
2024-02-29 4:38 pm |
2025-02-27 2034-02-26 |
NovoCure Ltd | NVCR | Leonard Frank X EVP, Pres., Novocure Oncology |
258,597 | $16.3 | 318,965 (Direct) |
View |
| 2024-02-27 Option Award |
2024-02-29 4:36 pm |
2025-02-27 2034-02-26 |
NovoCure Ltd | NVCR | Puri Michal Nath Chief Human Resources Officer |
181,017 | $16.3 | 218,610 (Direct) |
View |
| 2024-02-27 Option Award |
2024-02-29 4:35 pm |
2025-02-27 2034-02-26 |
NovoCure Ltd | NVCR | Weinberg Uri Chief Innovation Officer |
206,877 | $16.3 | 296,226 (Direct) |
View |
| 2024-02-27 Option Award |
2024-02-29 4:33 pm |
2025-02-27 2034-02-26 |
NovoCure Ltd | NVCR | Leupin Nicolas Chief Medical Officer |
129,298 | $16.3 | 129,298 (Direct) |
View |
| 2024-02-27 Option Award |
2024-02-29 4:33 pm |
2025-02-27 2034-02-26 |
NovoCure Ltd | NVCR | Giladi Moshe Chief Science Officer |
129,298 | $16.3 | 147,945 (Direct) |
View |
| 2024-02-27 Option Award |
2024-02-29 4:30 pm |
2025-02-27 2034-02-26 |
NovoCure Ltd | NVCR | Ben Arye Barak General Counsel |
206,877 | $16.3 | 242,200 (Direct) |
View |
| 2023-12-31 Option Award |
2024-02-29 4:30 pm |
N/A N/A |
NovoCure Ltd | NVCR | Ben Arye Barak General Counsel |
128 | $12.69 | 242,200 (Direct) |
View |
| 2024-02-27 Option Award |
2024-02-29 4:28 pm |
2025-02-27 2034-02-26 |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
118,954 | $16.3 | 326,479 (Direct) |
View |
| 2023-12-31 Option Award |
2024-02-29 4:28 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
3 | $12.69 | 326,479 (Direct) |
View |
Ownership |
2024-01-12 4:57 pm |
N/A N/A |
NovoCure Ltd | NVCR | Leonard Frank X EVP, Pres., Novocure Oncology |
0 | $0 | 227,173 (Direct) |
View |